Fig. 2.
Fig. 2. Caspases activation by ELL-12 treatment. Extracts from Jurkat T cells treated with 10 μg/mL ELL-12 for the indicated times were resolved by SDS-PAGE and probed with anti–caspase-3 (A), anti–caspase-7 (B), and anti–caspase-8 (C) antibodies. Cytosolic extracts from H9 cells (D) and U-937 cells (E) treated with 10 and 50 μg/mL ELL-12 or 50 ng/mL anti-Fas antibody for 16 hours were resolved by SDS-PAGE and probed with anti–caspase-3 antibody. The migration position of full-length caspase-3, the cleavage intermediate p20, the active subunit p17, the active caspase-7 subunit p20, full-length caspase-8, the cleavage intermediates p43 and p41, and the active subunit p18 are indicated.

Caspases activation by ELL-12 treatment. Extracts from Jurkat T cells treated with 10 μg/mL ELL-12 for the indicated times were resolved by SDS-PAGE and probed with anti–caspase-3 (A), anti–caspase-7 (B), and anti–caspase-8 (C) antibodies. Cytosolic extracts from H9 cells (D) and U-937 cells (E) treated with 10 and 50 μg/mL ELL-12 or 50 ng/mL anti-Fas antibody for 16 hours were resolved by SDS-PAGE and probed with anti–caspase-3 antibody. The migration position of full-length caspase-3, the cleavage intermediate p20, the active subunit p17, the active caspase-7 subunit p20, full-length caspase-8, the cleavage intermediates p43 and p41, and the active subunit p18 are indicated.

Close Modal

or Create an Account

Close Modal
Close Modal